Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.66 |
| ▸ | CIT | O14578 | 2/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267388 | 1.00 | GPR142 (0.66) | GPR142CITAAK1ROCK2MEN1 | |
| SCHEMBL4529357 | 0.85 | AAK1 (0.62) | GPR142CITAAK1ROCK2HDAC8 | |
| SCHEMBL4530047 | 0.84 | ROCK2 (0.69) | GPR142CITAAK1ROCK2MEN1 | |
| SCHEMBL4523463 | 0.84 | GPR142 (0.64) | GPR142CITAAK1ROCK2MEN1 | |
| SCHEMBL4521918 | 0.84 | GPR142 (0.64) | GPR142CITAAK1ROCK2MEN1 | |
| SCHEMBL2802593 | 0.84 | ROCK2 (0.64) | GPR142CITAAK1ROCK2MAPK1 | |
| SCHEMBL2802584 | 0.84 | ROCK2 (0.64) | GPR142CITAAK1ROCK2MAPK1 | |
| SCHEMBL10260826 | 0.84 | ROCK2 (0.64) | GPR142CITAAK1ROCK2MAPK1 | |
| Hydrochloric Acid SCHEMBL4525075 | 0.83 | ROCK2 (0.62) | GPR142CITAAK1ROCK2MAPK1 | |
| SCHEMBL7039856 | 0.82 | HDAC8 (0.66) | CITPOLBKMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | GPR142 3166/4885CIT 7/4885AAK1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.